federal_register: 2017-25676

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2017-25676 Determination of Regulatory Review Period for Purposes of Patent Extension; RAPIVAB Notice The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAPIVAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product. 2017-11-28 2017 11 https://www.federalregister.gov/documents/2017/11/28/2017-25676/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapivab https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25676.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAPIVAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of...

Links from other tables